Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage

Cancer Cell. 2010 Aug 9;18(2):171-84. doi: 10.1016/j.ccr.2010.07.001.


Two vascular growth factor families, VEGF and the angiopoietins, play critical and coordinate roles in tumor progression and metastasis. A single inhibitor targeting both VEGF and angiopoietins is not available. Here, we developed a chimeric decoy receptor, namely double anti-angiogenic protein (DAAP), which can simultaneously bind VEGF-A and angiopoietins, blocking their actions. Compared to VEGF-Trap or Tie2-Fc, which block either VEGF-A or angiopoietins alone, we believe DAAP is a highly effective molecule for regressing tumor angiogenesis and metastasis in implanted and spontaneous solid tumors; it can also effectively reduce ascites formation and vascular leakage in an ovarian carcinoma model. Thus, simultaneous blockade of VEGF-A and angiopoietins with DAAP is an effective therapeutic strategy for blocking tumor angiogenesis, metastasis, and vascular leakage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacokinetics
  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / toxicity
  • Angiopoietins / antagonists & inhibitors*
  • Animals
  • Capillary Permeability*
  • Cell Line, Tumor
  • Female
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Metastasis*
  • Neoplasm Transplantation
  • Neovascularization, Pathologic*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*


  • Angiogenesis Inhibitors
  • Angiopoietins
  • Vascular Endothelial Growth Factor A